Our Chief Operating Officer Nicolas Maignan will be representing Kantify and the DREAMS consortium at Medicines Reimagined, the International Drug Repurposing Conference 2025 (#iDR25) hosted by REMEDi4ALL and Beacon. The conference is taking place on 7 and 8 May 2025 in Amsterdam.

Goal of the conference

The conference aims to unlock the full potential of medicines by driving innovation for patient benefit. This global event will explore how cutting-edge artificial intelligence (AI) approaches are transforming drug discovery, alongside innovative business models and regulatory pathways for market access. You’ll engage with key opinion leaders across research and patient communities, policymakers, funders, regulators and the private sector.

Scope of the presentation

Nicolas Maignan will be speaking in the AI track of the conference, called "AI in Drug Repurposing".

In the field of repurposing, AI in-particular has seen extensive use in the identification of new repurposing opportunities, and the assessment of drug effects.

This track will explore the many different ways that AI is supporting the repurposing journey, its potential to further unlock the innovative use of existing medicines, and the challenges in the ethical and effective deployment of these rapidly advancing technologies in the highly sensitive world of health data.

Nicolas will present some of our recent results in target discovery for rare diseases, and will explain how our extremely promising results have led to the creation of of DREAMS, the European Commission funded international R&D project.

Conference

The agenda features thought-provoking plenaries, expert discussions and sessions on AI in clinical decision-making, new opportunities in drug repurposing, and addressing the needs of underserved populations - including rare diseases, rare cancers, and paediatric and rare infectious conditions. We'll also dive into innovative trial designs, policy, and pathways to improve patient access.